Regen Biopharma, Inc. balance sheet RGBPP

Annual Quarterly

As of Jun 30, 2026, Regen Biopharma, Inc. had total assets of $287,587 and total liabilities of $6.2 million. Total assets were up 46.1% from a year earlier. Stockholders' equity was negative, at -$5.9 million, because liabilities exceed assets. Cash and investments were $239. The current ratio, current assets divided by current liabilities, was 0.05.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Sep 30, 2025	FY 2024 Sep 30, 2024	FY 2023 Sep 30, 2023	FY 2022 Sep 30, 2022	FY 2020 Sep 30, 2020	FY 2019 Sep 30, 2019	FY 2018 Sep 30, 2018	FY 2017 Sep 30, 2017	FY 2016 Sep 30, 2016	FY 2016 Jun 30, 2016
Assets
Cash	0	0 +9614.4%	0	—	0 -93.0%	0 -100.0%	0 -2.0%	0 -97.0%	0	—	—
Cash and investments	0 -98.7%	0 +9614.4%	0	—	0 -93.0%	0 -100.0%	0 -2.0%	0 -97.0%	0	—	—
Receivables	0 +62.1%	0 +115.9%	0	0 -100.0%	0 +19.3%	0 +45.0%	0	0	0 -100.0%	0	—
Total current assets	0 +60.6%	0 +91.6%	0 +9.4%	0 -61.0%	0 -66.2%	0 +30.5%	0 +85.0%	0 -91.1%	0 +130.7%	0 +1846.1%	—
Total assets	0 +46.1%	0 +70.5%	0 -54.4%	0 -36.7%	1 -53.9%	0 +24.3%	0 -52.6%	0 -77.9%	1 +195.7%	0 +2897.2%	—
Liabilities and equity
Accounts payable	0 -32.3%	0 -94.2%	0 -0.0%	0 +3.0%	0 -68.5%	0 +20.1%	0 +14.2%	0 -83.7%	0 +105.9%	0 +7184.7%	—
Total current liabilities	6 +2.5%	7 +21.9%	5 +1.3%	5 -38.2%	9 -41.5%	7 -32.2%	11 +26.9%	9 +47.9%	6 +633.6%	1 +469.7%	—
Total liabilities	6 +2.5%	7 +21.9%	5 -1.5%	5 -36.5%	9 -41.5%	7 -32.2%	11 +18.0%	9 +50.6%	6 +583.6%	1 +546.0%	—
Stockholders' equity	-6 -1.1%	-6 -20.4%	-5 -2.2%	-5 +36.5%	-8	-7 +32.8%	-11 -19.6%	-9 -73.7%	-5 -820.9%	-1 -809.5%	-1 -789.3%
Debt
Debt due within a year	—	—	—	—	—	—	—	—	—	0	—
Total debt	—	—	—	—	—	—	—	—	—	0	—
Ratios
Current ratio	0.05x	0.04x	0.03x	0.02x	0.04x	0.01x	0.01x	0.00x	0.08x	0.26x	—
Return on assets	—	-464.08%	-414.85%	327.05%	437.12%	2,771.69%	-2,647.35%	-2,255.88%	-618.39%	-2,426.94%	—
Book value per share	-0.01	-0.16	-0.99	-1.46	-2.40	-0.00	-0.02	-0.05	-0.04	-0.00	-0.00

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: RGBP (OTC), RGBPP (OTC)
Fiscal year ends: September 30
Incorporated in: NV
Headquarters: La Mesa, CA
SEC filer status: , Emerging growth company
SEC CIK: 1589150

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.